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Abstract 
 
Purpose: To investigate the outcome of selective occlusion of the afferent vessel of corneal neovascular 
complexes (CoNV), using angiographically guided fine needle diathermy (FND).  
 
Design: Retrospective interventional case series  
 
Subjects: Patients with CoNV unresponsive to topical steroid therapy. 
 
Methods: Visual acuity, color images, and fluorescein angiography (FA) and indocyanine green 
angiography (ICGA) were measured before and following FND with a minimum of three months follow-
up.  The number of afferent vessels crossing the limbus, time to fluorescein leakage, area and geometric 
properties of the CoNV were determined using an in-house automated program written in numerical 
computing language (MatLab R14; The MathWorks Inc., Natick, MA).  The location of the afferent vessel 
was identified from the angiographic images and marked at the slit lamp using a needle to make a cut 
to the depth of the vessel.  FND was then applied using an electrolysis needle. 
 
Main Outcome Measure:  Area of CoNV  
 
Results: 30 patients underwent FND for CoNV that had not responded to treatment with topical 
steroids.  The CoNV was associated with previous microbial keratitis (26), intrastromal corneal ring 
segments (2), ectodermal dysplasia (1) and corneal choristoma (1). Duration of CoNV was over six 
months in the 23 patients (77%), between three and six months in 3 patients (10%), and less than 
three months in 5 patients (13%). The number of afferent vessels per CoNV complex ranged from 1 to 
3 with a mean diameter of 40μm (SD 10μm) and mean time to leakage from apical vessels was 44.22 
seconds (min: 27.43s max: 63.59s).  The number of episodes of FND treatments that were required was 
one for 20 patients (66.6%), two for 8 patients (26.6%) and three for 2 patients (6.6%). Following FND, 
the area of CoNV reduced by 1.80mm2 (SD: 1.40); from 2.42mm2 (SD: 1.59) to 0.62mm2 (SD: 0.73) up 
to 12 weeks post-operatively (p<0.01). 
 
Conclusions: The differentiation of afferent and efferent vessels using corneal angiography enables 
treatment to be selectively applied to the afferent vessels of which, there are usually 1 to 2 for each 
CoNV complex.  
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Fine needle diathermy is an easy and effective treatment for corneal neovascularization, 
however since its cellular effects are poorly understood, diathermy should be used sparingly. 
This can be achieved by angiographically-guided targeting of afferent vessels.  
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Abstract 33 
Purpose: To investigate the outcome of selective occlusion of the afferent vessel of corneal 34 
neovascular complexes (CoNV), using angiographically guided fine needle diathermy (FND).  35 
Design: Retrospective interventional case series  36 
Subjects: Patients with CoNV unresponsive to topical steroid therapy. 37 
Methods: Visual acuity, color images, and fluorescein angiography (FA) and indocyanine green 38 
angiography (ICGA) were measured before and following FND with a minimum of three months 39 
follow-up.  The number of afferent vessels crossing the limbus, time to fluorescein leakage, area and 40 
geometric properties of the CoNV were determined using an in-house automated program written in 41 
numerical computing language (MatLab R14; The MathWorks Inc., Natick, MA).  The location of the 42 
afferent vessel was identified from the angiographic images and marked at the slit lamp using a 43 
needle to make a cut to the depth of the vessel.  FND was then applied using an electrolysis needle. 44 
Main Outcome Measure:  Area of CoNV  45 
Results: 30 patients underwent FND for CoNV that had not responded to treatment with topical 46 
steroids.  The CoNV was associated with previous microbial keratitis (26), intrastromal corneal ring 47 
segments (2), ectodermal dysplasia (1) and corneal choristoma (1). Duration of CoNV was over six 48 
months in the 23 patients (77%), between three and six months in 3 patients (10%), and less than 49 
three months in 5 patients (13%). The number of afferent vessels per CoNV complex ranged from 1 50 
to 3 with a mean diameter of 40m (SD 10m) and mean time to leakage from apical vessels was 51 
44.22 seconds (min: 27.43s max: 63.59s).  The number of episodes of FND treatments that were 52 
required was one for 20 patients (66.6%), two for 8 patients (26.6%) and three for 2 patients (6.6%). 53 
Following FND, the area of CoNV reduced by 1.80mm2 (SD: 1.40); from 2.42mm2 (SD: 1.59) to 54 
0.62mm2 (SD: 0.73) up to 12 weeks post-operatively (p<0.01). 55 
Conclusions: The differentiation of afferent and efferent vessels using corneal angiography enables 56 
treatment to be selectively applied to the afferent vessels of which, there are usually 1 to 2 for each 57 
CoNV complex.  58 
59 
 3 
Introduction  60 
 61 
Avascularity of the cornea is important for its homeostasis and function. Corneal neovascularization 62 
(CoNV), however, may develop in response to hypoxia or inflammations, as infectious, allergic, toxic 63 
and traumatic injuries.1 The presence of CoNV reflects an imbalance between anti-angiogenic 64 
factors, such as pigment-epithelium-derived factor (PEDF), and angiogenic factors, such as fibroblast 65 
and vascular endothelial growth factors (VEGF).2, 3 CoNV is however, part of the wound healing 66 
response and may be useful in the acute phase for the transport of, humoral and cellular elements 67 
involved in immune response, materials required for repair and regeneration, removal of toxic 68 
substances and drugs to the site of inflammation.  Chronic up-regulation of the angiogenic response, 69 
however, results in the persistence of pathological new vessels, which have increased vascular 70 
permeability resulting in corneal oedema, lipid exudation, chronic or recurrent inflammation and 71 
scarring.4 There is also the potential establishment of lymphatics, normally absent from the cornea, 72 
which may further disrupt the “immune privilege” status of the cornea.4 73 
 74 
Various techniques have been employed to treat CoNV, including topical steroids, anti-VEGF, 75 
metalloproteinase inhibitors, photodynamic therapy, Argon laser, yellow dye laser, radiation, 76 
cryotherapy and conjunctival resection.4-6  Fine-needle diathermy (FND) has been described by 77 
several groups for the treatment of CoNV.5, 7-9 It involves the application of a coagulating current 78 
through a unipolar diathermy unit or thermal cautery, usually delivered through a needle such as a 79 
cutting or an electrolysis needle. Although FND has shown promise with the largest retrospective 80 
study reporting a series of 56 eyes, showing regression of CoNV in 89.3% of patients following two or 81 
less treatments.9  It is, however not known what long-term effects diathermy has on the cornea at a 82 
cellular level, particularly if applied to the multitude of vessels in the CoNV complexes.  Reducing the 83 
number of vessels that need to be closed may reduce the potential risks associated with FND and 84 
improve the efficacy of the procedure.  It is questionable whether both the afferent (presumed 85 
arteriole) and efferent (presumed venule) systems of CoNV require treatment and selective 86 
treatment to the afferent system may be sufficient. It is of note, that Cursiefen et al found that on 87 
histology, that arterioles tend to comprise less than 1% of CoNV.10  One option therefore, would be 88 
to only treat the afferent vessel(s) of the CoNV complex.11 While it is sometimes possible to 89 
distinguish afferent from efferent CoNV using slit lamp biomicroscopyat the slit lamp, it has been 90 
shown that the full extent and origin of the CoNV complex is not apparent often difficult to identify 91 
on color images.12-14  We have, however, recently shown that corneal angiography (fluorescein 92 
angiography, FA and indocyanine green angiography, ICGA) are particularly useful in identifying 93 
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vessels not seen on color images12-14, especially in the presence of corneal scars or inflammation and 94 
facilitate identification and differentiation of afferent and efferent vessels and vessel leakage.13  In 95 
order therefore, to minimise the amount of diathermy applied to the cornea, we describe the use of 96 
angiography to identify and specifically treat the afferent vessels using FND. 97 
 98 
Methods 99 
Patients who were undergoing FND for CoNV associated with previous corneal disease such as 100 
microbial keratitis and that had not responded to topical steroid therapy were included.  Topical 101 
steroids had been usedgiven for between 66 and 12 weeks duration.  Inclusion criteria were CoNV 102 
extending more than 3mm into cornea with varying degrees of lipid keratopathy and no active 103 
keratitis or corneal ulceration. Patients were followed up for a period of at least four months.  104 
Patients were examined with slit lamp biomicroscopy, and color and red free images, and FA and 105 
ICGA were obtained pre-treatment and three months post-treatment. IRB approval and informed 106 
consent were obtained and the Tenets of the Declaration of Helsinki were adhered to. 107 
 108 
Color, FA and ICGA images. 109 
Color images were captured using a slit lamp mounted digital system (Topcon SL-D Digital Slit Lamp, 110 
Tokyo, Japan) with 10 to 25 times magnification.  An HRA2 Scanning Laser Ophthalmoscope 111 
(Heidelberg Engineering, Heidelberg, Germany) with a 20 degree imaging lens set at 34 diopter (D), 112 
was used for ICGA and FA as previously described.12, 13 After injection of 5ml of indocyanine green 113 
dye (5mg/ml) (Pulsion Medical Systems, Germany)  videography was recorded for 25 seconds.  Single 114 
frame ICGA images of the whole cornea capturing corneal blood vessel fluorescence were taken 115 
every 3-5 seconds for 3 minutes followed by late images at 5 and 10 minutes.  An intravenous 116 
injection of 3mL of 20% Sodium fluorescein (Martindale Pharmaceuticals, Essex, UK) was then given 117 
and the videography repeated.  During the acquisition of single frame ICGA and FA images hi-118 
resolution mode with eye tracking automatic real-time (ART) software was used.  119 
 120 
Image analysis 121 
The region of interest (ROI) was defined pre-operatively as the area of the cornea containing the 122 
CoNV and was used to compare pre and post-operative images.  Images of pre- and final post-123 
operative angiograms of grade 3 or 4 were selected for analysis as previously described by two 124 
independent observers (SY and RD).12   The number of afferent vessels crossing the limbus and time 125 
to leakage of fluorescein were recorded.  The area and geometric properties of the vessels were 126 
determined on the selected images using an in-house automated program developed in Matlab R14 127 
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(The MathWorks Inc., Natick, MA). 13   In brief, the major steps of the program are as follows. For 128 
each image the pixel resolution (mm/pixel) was first defined as the ratio between the diameter of 129 
the cornea (mm) and the number of pixels measured manually from the image. A ROI containing all 130 
the corneal vessels was then defined by hand. The CoNV in the ROI was detected by applying 131 
Gaussian enhancement, selective vessel enhancement and thresholding techniques to the ROI in a 132 
sequential order.  In the resulting binary image (1 indicating vessel pixels while 0 indicating 133 
background pixels) the area of CoNV (mm2) was computed by multiplying the number of CoNV pixels 134 
and the area (mm2) occupied by a pixel. The centrelines of the vessels were identified by a ‘thinning’ 135 
operation so that the branch points and terminal points can be identified. The branching and 136 
terminal points were then used to divide the vascular tree into individual vessel segments.  The 137 
mean diameter (mm) of each segment can be computed so as to characterise the CoNV complex in 138 
the image. 139 
 140 
FND technique (Video) 141 
Afferent and efferent vessels were identified on videography (Figure 1) and the former labelled.  The 142 
annotated image was used as a reference to mark the afferent vessel(s) with an inked needle. Using 143 
slit lamp biomicroscopy, under topical anaesthesia, a partial thickness incision was made using a 25 144 
gauge needle on a 1 ml syringe into the posterior stroma over the identified afferent vessel(s) either 145 
at the limbus or at the level of marginal corneal arcades.15 If the afferent vessel was transected, an 146 
interruption of flow was evident in the visible vessels carrying red blood cells (Video). Under the 147 
operating microscope, an Ellman MH-EL-A2D fine wire electrolysis needle was then applied into the 148 
incision. Energy was delivered using a unipolar approach by a Surgitron® Dual RFTM machine (Ellman 149 
International Inc, Oceanside, NY, USA) using the lowest setting (1 joule per second) until a visible 150 
blanching of the cornea around the afferent vessel was seen and segmentation of the blood flow in 151 
the larger efferent vessels if not already present. Patients received guttae prednisolone 1% qds and 152 
chloramphenicol 0.5% qds post-operatively for 4 weeks only. 153 
 154 
Statistical analysis 155 
A Mann Whitney test was used to compare pre- and post-operative area of CoNV and a paired 156 
samples t-test for change in visual acuity (SPSS Statistics 21). 157 
 158 
Results 159 
30 patients (mean age 56 years, range: 23 to 95 years, male:female::1:1) undergoing FND for CoNV 160 
were included.  Demographic details as well as diagnoses and previous treatments are provided in 161 
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Table 1. The causes of the CoNV were previous herpes simplex keratitis (HSK) (13), clinically 162 
suspected bacterial keratitis (13), vascularization associated with intrastromal corneal ring segments 163 
(2), ectodermal dysplasia (1) and corneal choristoma (1). The duration of CoNV at time of FND was 164 
over six months in the 23 patients (77%), between three and six months in 3 patients (10%), and less 165 
than three months in 5 patients (13%).  The number of FND treatments performed was single 166 
treatment for 20 patients (66.6%), two for 8 patients (26.6%) and three for 2 patients (6.6%) (Table 167 
1). 168 
The number of afferent vessels per CoNV complex ranged from 1 to 2 with a mean diameter of 169 
40m (SD: 10m) (Table 2). The mean time to leakage from the apical vessels on fluorescein 170 
angiography was 44.22 seconds (min: 27.43s, max: 63.59s). The area of CoNV reduced from 171 
2.42mm2 (SD: 1.59) to 0.62mm2 (SD: 0.73) post-operatively (p<0.01), a mean reduction of 1.80mm2 172 
(SD: 1.40).  The percentage reduction in area of CoNV for each patient is shown in Table 2. Although 173 
the area of CoNV reduced post-treatment (Figure 2), FND did not lead to a complete closure of the 174 
entire CoNV complexes in all patients with some residual vessels in the periphery of the cornea. 175 
There was statistically significant improvement in BCVA from 0.59 (SD: 0.71) to 0.40 (SD: 0.42) post-176 
treatment , t(29) = 2.32, two tail (p =0.027) with, and a mean change of 0.17 LogMAR (Table 1).  177 
Adverse events and reactions included peripheral corneal thinning (Patient 6), intrastromal 178 
haemorrhage, which cleared spontaneously (Patient 11), recurrence of herpes simplex keratitis 179 
(Patients 9 and 11) and a change in refractive error (Patient 1). 180 
 181 
Discussion 182 
The presence of CoNV threatens the functional integrity of the cornea with the risk of lipid 183 
exudation, loss of transparency, loss of visual acuity, increased inflammatory response and an 184 
increased risk of graft failure.  To date, there is no universally accepted treatment strategy to 185 
successfully treat CoNV although topical steroids are perhaps the most commonly employed 186 
treatment.4  Topical and injected anti-VEGF has been utilised in the treatment of CoNV, however, it 187 
has been suggested that once vessels mature and acquire a pericyte-covered wall, they are no 188 
longer dependent on VEGF for growth and are thus unresponsive to anti-VEGF.16,17 Argon laser has 189 
been shown to have limited efficacy and with a risk of complications such as iris atrophy.4, 7 The 190 
speed of red blood cell movement in afferent vessels and their usual deeper location in the cornea 191 
makes them relatively insensitive to Argon laser. 192 
 193 
FND has shown promising short-term results for treatment of CoNV.  Trikha et al reported FND to be 194 
a safe and effective in the medium to long term, with mean follow-up of 18.9 months (range 1 - 56 195 
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months).  They reported only one complication, that of corneal and subconjunctival haemorrhage in 196 
their large series of patients, and also demonstrated a significant improvement in LogMAR VA from 197 
0.82 pre-treatment to 0.72 post-treatment.9  FND, has however, has been applied without 198 
distinction to afferent or efferent vessels, usually to the larger vessels identified on color images.18  199 
The larger vessels and more numerous vessels that are identified on color images, slit lamp 200 
biomicroscopy are efferent vessels so that FND applied to these vessels may not be as effective as if 201 
applied to the afferent vessels, which are narrower and slightly less tortuous. In particular, the 202 
differentiation of afferent and efferent vessels aided by corneal angiography enables such treatment 203 
to be applied to the afferent vessels of which, there are usually only 1 to 2 for each CoNV complex. 204 
Although in some cases it may be possible to differentiate afferent and efferent vessels on slit lamp 205 
biomicroscopy, aided for example by the patient’s pulse, this can be difficult. Once the afferent 206 
vessel or vessels have been identified on angiography, however, it then makes the identification on 207 
slit lamp biomicroscopy more apparent and reliable.In particular, the differentiation of afferent and 208 
efferent vessels using corneal angiography enables such treatment to be applied to the afferent 209 
vessels of which there are usually only 1 to 2 for each CoNV complex.   210 
 211 
FND is a relatively easy procedure to perform with only a few minor complications reported, 212 
including transient whitening of the cornea and intrastromal haemorrhage, which usually resolves 213 
without sequelae,5, 7 recurrent HSK and localised thinning and ectasia.7  The cellular changes that 214 
occur following FND, however, are less well understood.  In rats, a significant increase in the number 215 
of B7+ MHC II+ Langerhans cells in the limbal surface epithelium occurs within hours of cautery, and 216 
later throughout the entire corneal epithelium, suggesting an inflammatory reactionas well as of 217 
these cells the central cornea, where they are normally absent.19  Langerhans cells are the 218 
professional antigen-presenting cells of the corneal epithelium, and their absence from the central 219 
cornea plays an important role in maintaining the immune privilege of the cornea. In addition, 220 
Feldman et al,  in an experimental study on rabbits showed  that radial thermokeratoplasty caused 221 
significant damage to the corneal endothelium beneath and surrounding the coagulation site.20  222 
Furthermore corneal heating reduces corneal curvature, with therapeutic potential for correction of 223 
myopia and as a treatment for corneal ectasia.21,22  AHowever at a molecular level, however, it 224 
results in shrinkage of corneal stromal collagen.22  It is also unclear what the long-term effects of 225 
diathermy to the cornea may be. The process of corneal diathermy itself may be a stimulus for 226 
further CoNV. It would therefore seem reasonable, to try and minimise the application of FND to the 227 
cornea.  ICGA or FA offers the ability to identify the afferent or feeder vessels for FND, and 228 
application of anti-angiogenic factors such as anti-VEGF may be better applied to less mature or 229 
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 8 
immature vessels,17 which can be identified using time to leakage on FA.12, 13  In particular topically 230 
applied pazopanib, a selective multi-targeted receptor tyrosine kinase inhibitor of VEGF receptor and 231 
platelet derived growth factor (PDGF) receptor has shown promise in the treatment of CoNV.15 232 
 233 
Our results suggest that angiographically-guided FND, targeting the afferent vessels may be effective 234 
in reducing the area of CoNV.  In our series, although around a third of patients required 235 
retreatment, this may reflect identification of vessels on angiography that are not apparent on 236 
colour images.11-14 Similar to Trikha et al9, adverse events were uncommon and mostly transient, and 237 
there was an small improvement in visual acuity.  In those patients undergoing corneal 238 
transplantation, the reduction in CoNV may be of benefit.   Since the long-term effects of FND are 239 
poorly understood, it is the authors’ opinion that diathermy should be used sparingly. The 240 
differentiation of afferent and efferent vessels aided byusing corneal angiography, enables such 241 
treatment to be applied to the afferent vessels, of which there are usually only 1 to 2 for each CoNV 242 
complex. 243 
 244 
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Figure Captions 328 
 329 
Figure 1. Identification of afferent and efferent vessels. 330 
The 3 afferent vessels (two superiorly and one inferiorly are identified as the first to fluoresce in the 331 
angiogram (arrows in A). As the angiogram is continued (B and C) the efferent vessels fill and 332 
become prominent (arrows).  Note the larger efferent vessels partially overlying and obscuring the 333 
narrower afferent vessels (D).  334 
 335 
Figure 2. Treatment of CoNV effect following FND. 336 
Pre (A) and post-treatment closure of CoNV (B) following occlusion of the afferent vessel with FND. 337 
Note the narrower and less tortuous afferent vessel compared to the more obvious efferent vessels 338 
draining the complex. 339 
 340 
Video 341 
Transection of afferent vessel using a 25 gauge needle.  Note the stagnation of flow in the larger 342 
efferent vessels.  343 
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Abstract 33 
Purpose: To investigate the outcome of selective occlusion of the afferent vessel of corneal 34 
neovascular complexes (CoNV), using angiographically guided fine needle diathermy (FND).  35 
Design: Retrospective interventional case series  36 
Subjects: Patients with CoNV unresponsive to topical steroid therapy. 37 
Methods: Visual acuity, color images, and fluorescein angiography (FA) and indocyanine green 38 
angiography (ICGA) were measured before and following FND with a minimum of three months 39 
follow-up.  The number of afferent vessels crossing the limbus, time to fluorescein leakage, area and 40 
geometric properties of the CoNV were determined using an in-house automated program written in 41 
numerical computing language (MatLab R14; The MathWorks Inc., Natick, MA).  The location of the 42 
afferent vessel was identified from the angiographic images and marked at the slit lamp using a 43 
needle to make a cut to the depth of the vessel.  FND was then applied using an electrolysis needle. 44 
Main Outcome Measure:  Area of CoNV  45 
Results: 30 patients underwent FND for CoNV that had not responded to treatment with topical 46 
steroids.  The CoNV was associated with previous microbial keratitis (26), intrastromal corneal ring 47 
segments (2), ectodermal dysplasia (1) and corneal choristoma (1). Duration of CoNV was over six 48 
months in the 23 patients (77%), between three and six months in 3 patients (10%), and less than 49 
three months in 5 patients (13%). The number of afferent vessels per CoNV complex ranged from 1 50 
to 3 with a mean diameter of 40m (SD 10m) and mean time to leakage from apical vessels was 51 
44.22 seconds (min: 27.43s max: 63.59s).  The number of episodes of FND treatments that were 52 
required was one for 20 patients (66.6%), two for 8 patients (26.6%) and three for 2 patients (6.6%). 53 
Following FND, the area of CoNV reduced by 1.80mm2 (SD: 1.40); from 2.42mm2 (SD: 1.59) to 54 
0.62mm2 (SD: 0.73) up to 12 weeks post-operatively (p<0.01). 55 
Conclusions: The differentiation of afferent and efferent vessels using corneal angiography enables 56 
treatment to be selectively applied to the afferent vessels of which, there are usually 1 to 2 for each 57 
CoNV complex.  58 
59 
 3 
Introduction  60 
 61 
Avascularity of the cornea is important for its homeostasis and function. Corneal neovascularization 62 
(CoNV), however, may develop in response to hypoxia or inflammations, as infectious, allergic, toxic 63 
and traumatic injuries.1 The presence of CoNV reflects an imbalance between anti-angiogenic 64 
factors, such as pigment-epithelium-derived factor (PEDF), and angiogenic factors, such as fibroblast 65 
and vascular endothelial growth factors (VEGF).2, 3 CoNV is however, part of the wound healing 66 
response and may be useful in the acute phase for the transport of, humoral and cellular elements 67 
involved in immune response, materials required for repair and regeneration, removal of toxic 68 
substances and drugs to the site of inflammation.  Chronic up-regulation of the angiogenic response, 69 
however, results in the persistence of pathological new vessels, which have increased vascular 70 
permeability resulting in corneal oedema, lipid exudation, chronic or recurrent inflammation and 71 
scarring.4 There is also the potential establishment of lymphatics, normally absent from the cornea, 72 
which may further disrupt the “immune privilege” status of the cornea.4 73 
 74 
Various techniques have been employed to treat CoNV, including topical steroids, anti-VEGF, 75 
metalloproteinase inhibitors, photodynamic therapy, Argon laser, yellow dye laser, radiation, 76 
cryotherapy and conjunctival resection.4-6  Fine-needle diathermy (FND) has been described by 77 
several groups for the treatment of CoNV.5, 7-9 It involves the application of a coagulating current 78 
through a unipolar diathermy unit or thermal cautery, usually delivered through a needle such as a 79 
cutting or an electrolysis needle. FND has shown promise with the largest retrospective study 80 
reporting a series of 56 eyes, showing regression of CoNV in 89.3% of patients following two or less 81 
treatments.9  It is, however not known what effects diathermy has on the cornea at a cellular level, 82 
particularly if applied to the multitude of vessels in the CoNV complexes.  Reducing the number of 83 
vessels that need to be closed may reduce the potential risks associated with FND and improve the 84 
efficacy of the procedure.  It is questionable whether both the afferent (presumed arteriole) and 85 
efferent (presumed venule) systems of CoNV require treatment and selective treatment to the 86 
afferent system may be sufficient. It is of note, that Cursiefen et al found that on histology, that 87 
arterioles tend to comprise less than 1% of CoNV.10  One option therefore, would be to only treat the 88 
afferent vessel(s) of the CoNV complex.11 While it is sometimes possible to distinguish afferent from 89 
efferent CoNV using slit lamp biomicroscopy, it has been shown that the full extent and origin of the 90 
CoNV complex is not apparent on color images.12-14  We have, however, recently shown that corneal 91 
angiography (fluorescein angiography, FA and indocyanine green angiography, ICGA) are particularly 92 
useful in identifying vessels not seen on color images12-14, especially in the presence of corneal scars 93 
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or inflammation and facilitate identification and differentiation of afferent and efferent vessels and 94 
vessel leakage.13  In order therefore, to minimise the amount of diathermy applied to the cornea, we 95 
describe the use of angiography to identify and specifically treat the afferent vessels using FND. 96 
 97 
Methods 98 
Patients who were undergoing FND for CoNV associated with previous corneal disease such as 99 
microbial keratitis and that had not responded to topical steroid therapy were included.  Topical 100 
steroids had been used for between 6 and 12 weeks duration.  Inclusion criteria were CoNV 101 
extending more than 3mm into cornea with varying degrees of lipid keratopathy and no active 102 
keratitis or corneal ulceration. Patients were followed up for a period of at least four months.  103 
Patients were examined with slit lamp biomicroscopy, and color and red free images, and FA and 104 
ICGA were obtained pre-treatment and three months post-treatment. IRB approval and informed 105 
consent were obtained and the Tenets of the Declaration of Helsinki were adhered to. 106 
 107 
Color, FA and ICGA images. 108 
Color images were captured using a slit lamp mounted digital system (Topcon SL-D Digital Slit Lamp, 109 
Tokyo, Japan) with 10 to 25 times magnification.  An HRA2 Scanning Laser Ophthalmoscope 110 
(Heidelberg Engineering, Heidelberg, Germany) with a 20 degree imaging lens set at 34 diopter (D), 111 
was used for ICGA and FA as previously described.12, 13 After injection of 5ml of indocyanine green 112 
dye (5mg/ml) (Pulsion Medical Systems, Germany)  videography was recorded for 25 seconds.  Single 113 
frame ICGA images of the whole cornea capturing corneal blood vessel fluorescence were taken 114 
every 3-5 seconds for 3 minutes followed by late images at 5 and 10 minutes.  An intravenous 115 
injection of 3mL of 20% Sodium fluorescein (Martindale Pharmaceuticals, Essex, UK) was then given 116 
and the videography repeated.  During the acquisition of single frame ICGA and FA images hi-117 
resolution mode with eye tracking automatic real-time (ART) software was used.  118 
 119 
Image analysis 120 
The region of interest (ROI) was defined pre-operatively as the area of the cornea containing the 121 
CoNV and was used to compare pre and post-operative images.  Images of pre- and final post-122 
operative angiograms of grade 3 or 4 were selected for analysis as previously described by two 123 
independent observers (SY and RD).12   The number of afferent vessels crossing the limbus and time 124 
to leakage of fluorescein were recorded.  The area and geometric properties of the vessels were 125 
determined on the selected images using an in-house automated program developed in Matlab R14 126 
(The MathWorks Inc., Natick, MA). 13   In brief, the major steps of the program are as follows. For 127 
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each image the pixel resolution (mm/pixel) was first defined as the ratio between the diameter of 128 
the cornea (mm) and the number of pixels measured manually from the image. A ROI containing all 129 
the corneal vessels was then defined by hand. The CoNV in the ROI was detected by applying 130 
Gaussian enhancement, selective vessel enhancement and thresholding techniques to the ROI in a 131 
sequential order.  In the resulting binary image (1 indicating vessel pixels while 0 indicating 132 
background pixels) the area of CoNV (mm2) was computed by multiplying the number of CoNV pixels 133 
and the area (mm2) occupied by a pixel. The centrelines of the vessels were identified by a ‘thinning’ 134 
operation so that the branch points and terminal points can be identified. The branching and 135 
terminal points were then used to divide the vascular tree into individual vessel segments.  The 136 
mean diameter (mm) of each segment can be computed so as to characterise the CoNV complex in 137 
the image. 138 
 139 
FND technique (Video) 140 
Afferent and efferent vessels were identified on videography (Figure 1) and the former labelled.  The 141 
annotated image was used as a reference to mark the afferent vessel(s) with an inked needle. Using 142 
slit lamp biomicroscopy, under topical anaesthesia, a partial thickness incision was made using a 25 143 
gauge needle on a 1 ml syringe into the posterior stroma over the identified afferent vessel(s) either 144 
at the limbus or at the level of marginal corneal arcades.15 If the afferent vessel was transected, an 145 
interruption of flow was evident in the visible vessels carrying red blood cells (Video). Under the 146 
operating microscope, an Ellman MH-EL-A2D fine wire electrolysis needle was then applied into the 147 
incision. Energy was delivered using a unipolar approach by a Surgitron® Dual RFTM machine (Ellman 148 
International Inc, Oceanside, NY, USA) using the lowest setting (1 joule per second) until a visible 149 
blanching of the cornea around the afferent vessel was seen and segmentation of the blood flow in 150 
the larger efferent vessels if not already present. Patients received guttae prednisolone 1% qds and 151 
chloramphenicol 0.5% qds post-operatively for 4 weeks only. 152 
 153 
Statistical analysis 154 
A Mann Whitney test was used to compare pre- and post-operative area of CoNV and a paired 155 
samples t-test for change in visual acuity (SPSS Statistics 21). 156 
 157 
Results 158 
30 patients (mean age 56 years, range: 23 to 95 years, male:female::1:1) undergoing FND for CoNV 159 
were included.  Demographic details as well as diagnoses and previous treatments are provided in 160 
Table 1. The causes of the CoNV were previous herpes simplex keratitis (HSK) (13), clinically 161 
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suspected bacterial keratitis (13), vascularization associated with intrastromal corneal ring segments 162 
(2), ectodermal dysplasia (1) and corneal choristoma (1). The duration of CoNV at time of FND was 163 
over six months in the 23 patients (77%), between three and six months in 3 patients (10%), and less 164 
than three months in 5 patients (13%).  The number of FND treatments performed was single 165 
treatment for 20 patients (66.6%), two for 8 patients (26.6%) and three for 2 patients (6.6%) (Table 166 
1). 167 
The number of afferent vessels per CoNV complex ranged from 1 to 2 with a mean diameter of 168 
40m (SD: 10m) (Table 2). The mean time to leakage from the apical vessels on fluorescein 169 
angiography was 44.22 seconds (min: 27.43s, max: 63.59s). The area of CoNV reduced from 170 
2.42mm2 (SD: 1.59) to 0.62mm2 (SD: 0.73) post-operatively (p<0.01), a mean reduction of 1.80mm2 171 
(SD: 1.40).  The percentage reduction in area of CoNV for each patient is shown in Table 2. Although 172 
the area of CoNV reduced post-treatment (Figure 2), FND did not lead to a complete closure of the 173 
entire CoNV complexes in all patients with some residual vessels in the periphery of the cornea. 174 
There was significant improvement in BCVA from 0.59 (SD: 0.71) to 0.40 (SD: 0.42) post-treatment (p 175 
=0.027) with a mean change of 0.17 LogMAR (Table 1).  Adverse events and reactions included 176 
peripheral corneal thinning (Patient 6), intrastromal haemorrhage, which cleared spontaneously 177 
(Patient 11), recurrence of herpes simplex keratitis (Patients 9 and 11) and a change in refractive 178 
error (Patient 1). 179 
 180 
Discussion 181 
The presence of CoNV threatens the functional integrity of the cornea with the risk of lipid 182 
exudation, loss of transparency, loss of visual acuity, increased inflammatory response and an 183 
increased risk of graft failure.  To date, there is no universally accepted treatment strategy to 184 
successfully treat CoNV although topical steroids are perhaps the most commonly employed 185 
treatment.4  Topical and injected anti-VEGF has been utilised in the treatment of CoNV, however, it 186 
has been suggested that once vessels mature and acquire a pericyte-covered wall, they are no 187 
longer dependent on VEGF for growth and are thus unresponsive to anti-VEGF.16,17 Argon laser has 188 
been shown to have limited efficacy and with a risk of complications such as iris atrophy.4, 7 The 189 
speed of red blood cell movement in afferent vessels and their usual deeper location in the cornea 190 
makes them relatively insensitive to Argon laser. 191 
 192 
FND has shown promising results for treatment of CoNV.  Trikha et al reported FND to be safe and 193 
effective in the medium to long term, with mean follow-up of 18.9 months (range 1 - 56 months).  194 
They reported only one complication, that of corneal and subconjunctival hemorrhage and also 195 
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demonstrated a significant improvement in LogMAR VA from 0.82 pre-treatment to 0.72 post-196 
treatment.9  FND, however, has been applied without distinction to afferent or efferent vessels, 197 
usually to the larger vessels identified on color images.18  The larger vessels and more numerous 198 
vessels that are identified on color images, slit lamp biomicroscopy are efferent vessels so that FND 199 
applied to these vessels may not be as effective as if applied to the afferent vessels, which are 200 
narrower and slightly less tortuous. In particular, the differentiation of afferent and efferent vessels 201 
aided by corneal angiography enables such treatment to be applied to the afferent vessels of which, 202 
there are usually only 1 to 2 for each CoNV complex. Although in some cases it may be possible to 203 
differentiate afferent and efferent vessels on slit lamp biomicroscopy, aided for example by the 204 
patient’s pulse, this can be difficult. Once the afferent vessel or vessels have been identified on 205 
angiography, however, it then makes the identification on slit lamp biomicroscopy more apparent 206 
and reliable. 207 
 208 
FND is a relatively easy procedure to perform with only a few minor complications reported, 209 
including transient whitening of the cornea and intrastromal haemorrhage, which usually resolves 210 
without sequelae,5, 7 recurrent HSK and localised thinning and ectasia.7  The cellular changes that 211 
occur following FND, however, are less well understood.  In rats, a significant increase in the number 212 
of B7+ MHC II+ Langerhans cells in the limbal surface epithelium occurs within hours of cautery, and 213 
later throughout the entire corneal epithelium, suggesting an inflammatory reaction.19  In addition, 214 
Feldman et al, showed  that radial thermokeratoplasty caused significant damage to the corneal 215 
endothelium beneath and surrounding the coagulation site.20  Furthermore corneal heating reduces 216 
corneal curvature, with therapeutic potential for correction of myopia and as a treatment for 217 
corneal ectasia.21,22  At a molecular level, however, it results in shrinkage of corneal stromal 218 
collagen.22  It is also unclear what the long-term effects of diathermy to the cornea may be. The 219 
process of corneal diathermy itself may be a stimulus for further CoNV. It would therefore seem 220 
reasonable, to try and minimise the application of FND to the cornea.  ICGA or FA offers the ability to 221 
identify the afferent or feeder vessels for FND, and application of anti-angiogenic factors such as 222 
anti-VEGF may be better applied to less mature or immature vessels,17 which can be identified using 223 
time to leakage on FA.12, 13  In particular topically applied pazopanib, a selective multi-targeted 224 
receptor tyrosine kinase inhibitor of VEGF receptor and platelet derived growth factor (PDGF) 225 
receptor has shown promise in the treatment of CoNV.15 226 
 227 
Our results suggest that angiographically-guided FND, targeting the afferent vessels may be effective 228 
in reducing the area of CoNV.  In our series, although around a third of patients required 229 
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retreatment, this may reflect identification of vessels on angiography that are not apparent on 230 
colour images.11-14 Similar to Trikha et al9, adverse events were uncommon and mostly transient, and 231 
there was an improvement in visual acuity. Since the long-term effects of FND are poorly 232 
understood, it is the authors’ opinion that diathermy should be used sparingly. The differentiation of 233 
afferent and efferent vessels aided by corneal angiography, enables such treatment to be applied to 234 
the afferent vessels, of which there are usually only 1 to 2 for each CoNV complex. 235 
 236 
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Figure Captions 315 
 316 
Figure 1. Identification of afferent and efferent vessels. 317 
The 3 afferent vessels (two superiorly and one inferiorly are identified as the first to fluoresce in the 318 
angiogram (arrows in A). As the angiogram is continued (B and C) the efferent vessels fill and 319 
become prominent (arrows).  Note the larger efferent vessels partially overlying and obscuring the 320 
narrower afferent vessels (D).  321 
 322 
Figure 2. Treatment of CoNV effect following FND. 323 
Pre (A) and post-treatment closure of CoNV (B) following occlusion of the afferent vessel with FND. 324 
Note the narrower and less tortuous afferent vessel compared to the more obvious efferent vessels 325 
draining the complex. 326 
 327 
Video 328 
Transection of afferent vessel using a 25 gauge needle.  Note the stagnation of flow in the larger 329 
efferent vessels.  330 
Table 1 Patient demographics, diagnosis, treatment and outcomes. 
 
Patient Age Diagnosis** Sex 
Duration 
(months) of 
CoNV 
 
Treatment prior to FND * 
N°. of  
FND 
Adverse reactions 
Pre-op 
BCVA 
(logMAR) 
Post-op 
BCVA 
(logMAR) 
1 74 HSK F >6 Aciclovir 1 None 0.18 0 
2 56 BK (S.aureus) F 3-6 Antimicrobial  1 None 0 0.2 
3 23 Corneal choristoma F >6 Bevacizumab 1 None 0 0 
4 54 HSK M <3  Aciclovir 1 None 0.6 0.6 
5 70 BK (S.aureus) M >6 Aciclovir, Antimicrobial  1 None 0.18 0.18 
6 70 HSK M >6 Aciclovir 1 Peripheral thinning 0.6 0.48 
7 79 BK (S. aureus) M >6 Antimicrobial 3 None 0.3 0.3 
8 78 BK (S. aureus)  F >6 Antimicrobial 1 None 0.3 0.5 
9 70 HSK F >6 Aciclovir 2 Recurrence of HSK 0.18 0.18 
10 54 BK  M >6 Antimicrobial 1 None 1 0.78 
11 47 HSK M >6 Aciclovir 2 
Recurrence of HSK , 
intrastromal hemorrhage 
0.18 0.18 
12 70 BK (S.aureus) M >6 Antimicrobial  1 None 0.3 0.3 
13 22 BK (P. aeruginosa) M >6 Antimicrobial 1 None -0.2  -0.2 
14 84 BK (S.aureus)  M 3-6 Antimicrobial 1 None 0.18 0.18 
15 52 HSK M >6 Aciclovir, Antimicrobial 1 Refractive error  0.18 0.18 
16 39 BK (S.aureus) F 3-6 Antimicrobial 2 None 0.3 0.18 
17 34 KC (Intacs) M <3    1 None 3 2 
18 34 HSK M >6 Aciclovir, Foscarnet 1 None 0.18 0 
19 59 BK (S.aureus)  M >6 Antimicrobial, Argon laser 1 None 0.5 0.6 
20 67 HSK F >6 Aciclovir 2 None 1.3 0.67 
21 47 Ectodermal dysplasia F >6 Retinoic acid 3 None 0.48 0.48 
22 69 HSK F <3 Aciclovir 1 None 0.18 0.18 
23 44 BK (S.aureus) M <3 Antimicrobial 2 None 1 0.3 
24 71 BK (P. aeruginosa) M >6 Antimicrobial 2 None 0.6 1 
25 95 HSK F >6 Argon laser 2 None 1 0.8 
26 25 HSK F <3  Aciclovir 1 None 2 0.48 
27 35 KC (Intacs) F >6   1 None 0.18  0.18  
28 62 HSK F >6 Aciclovir 1 None 2 0.6 
29 24 HSK F >6 Aciclovir 2 None 0 0 
30 62 BK (S. aureus) F >6 Antimicrobial 1 None  1 0.78 
Mean 56       0.59 0.40 
SD 19.72       0.71 0.42 
 
Footnotes: *All the patient had received topical stereoids before and after treatment.; HSK: Herpes Simplex Keratits, KC: keratoconus; BK: 
bacterial keratitis, LSCD: Limbal stem cell deficiency, ACV: aciclovir, AM: antimicrobials. Diagnosis** type of bacteria if isolated 
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Table 2. Data on pre- and post-operative outcomes 
 
 
Patient 
number 
Area of CoNV (mm
2
) 
Percentage 
change 
Afferent vessels Time to 
leakage on 
pre-op FFA 
(s) 
Pre-op Post-op Change 
Diameter 
(mm) 
Number on 
pre-op 
angiogram 
1 0.89 0 -0.89 100 0.04 1 27.43 
2 2.89 0 -2.89 100 0.04 2.5 28.28 
3 0.5 0 -0.5 100 0.06 1 38.26 
4 3.13 0 -3.13 100 0.03 1 30.83 
5 0.25 0 -0.25 100 0.04 3 63.59 
6 0.98 0 -0.98 100 0.07 2 48.9 
7 2.42 0 -2.42 100 0.05 2 41.7 
8 0.96 0 -0.96 100 0.04 1.5 33.91 
9 4.04 0.12 -3.92 97 0.03 1 30 
10 5.09 0.44 -4.65 91 0.05 2 41.82 
11 3.81 0.36 -3.45 91 0.03 2 32.37 
12 5.67 0.61 -5.06 89 0.05 2.5 41 
13 2.85 0.41 -2.44 86 0.04 1 27.98 
14 2.84 0.44 -2.4 85 0.05 2.5 34.79 
15 0.95 0.19 -0.75 79 0.05 1 35.71 
16 0.13 0.04 -0.1 77 0.03 1 43.18 
17 0.5 0.12 -0.38 76 0.03 2 33.41 
18 2.52 0.61 -1.9 75 0.04 2 42.31 
19 2.11 0.61 -1.5 71 0.08 3 55.8 
20 5.54 1.62 -3.91 71 0.05 2 32.01 
21 4.6 1.48 -3.11 68 0.04 3 50.91 
22 3.17 1.11 -2.07 65 0.04 1 38.19 
23 3.02 1.16 -1.86 62 0.03 1 33.64 
24 2.1 1.02 -1.08 51 0.04 2 28.15 
25 2.49 1.46 -1.03 41 0.05 1 28.01 
26 0.77 0.51 -0.25 32 0.03 1 30.5 
27 0.6 0.41 -0.19 32 0.04 1 27.87 
28 1.82 1.26 -0.56 31 0.05 3 40.1 
29 1.52 1.13 -0.39 26 0.05 3 49.19 
30 4.37 3.46 -0.91 21 0.05 2 36.85 
        
Mean 2.42 0.62 -1.80 74 0.04 1.80 37,55 
SD 1.59 0.73 1.40  0.01 0.75 9.06 
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